Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$4.64
-1.3%
$3.91
$2.76
$13.11
$489.10M-1.47682,269 shs325,179 shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
$3.41
$1.79
$6.30
$524.83M1.17N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.85
-21.9%
$2.04
$0.79
$8.32
$48.42M0.266.05 million shs18.20 million shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$9.07
-2.5%
$10.59
$6.19
$13.16
$522.06M1.871.64 million shs966,453 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-1.28%-4.13%+13.17%+31.44%-63.78%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%+15.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-21.91%-68.24%-58.48%-53.99%-88.70%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-2.47%-3.92%-17.47%+6.46%+24.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
3.0396 of 5 stars
3.60.00.00.03.31.71.3
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.3943 of 5 stars
1.10.00.00.02.70.80.6
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.6325 of 5 stars
4.22.00.00.02.90.00.6
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.2435 of 5 stars
4.53.00.00.01.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.13
Buy$20.17334.63% Upside
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
2.17
Hold$1.33-60.90% Downside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.33
Hold$9.601,027.82% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.89
Moderate Buy$23.71161.46% Upside

Current Analyst Ratings Breakdown

Latest OTLK, ZVRA, OPT, and ALMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
8/27/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/18/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/15/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00
8/14/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
8/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $18.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$17.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$4.66 per shareN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$120K4,373.61N/AN/A($0.56) per share-6.09
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($0.84) per shareN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$23.61M21.56N/AN/A$2.09 per share4.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-119.15%-92.50%11/12/2025 (Estimated)
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
-$220.24MN/A0.00N/AN/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$105.51M-$0.21N/A45.35N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)

Latest OTLK, ZVRA, OPT, and ALMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million
8/13/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11-$1.17-$0.06$0.77$1.80 million$2.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
6.05
6.05
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/A
1.57
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.67
0.54
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.52
7.85
7.81

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
55.95%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
3.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A104.06 million61.71 millionN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
8153.91 million148.99 millionNot Optionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2044.42 million42.29 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2056.13 million54.79 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alumis stock logo

Alumis NASDAQ:ALMS

$4.64 -0.06 (-1.28%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$4.65 +0.01 (+0.19%)
As of 08/29/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)
As of 08/29/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.85 -0.24 (-21.91%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.87 +0.02 (+1.86%)
As of 08/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$9.07 -0.23 (-2.47%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$9.07 0.00 (0.00%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.